Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis
β Scribed by Liliana Montella; Carmela Merola; Geraldina Merola; Luigi Petillo; Giovannella Palmieri
- Publisher
- Springer
- Year
- 2008
- Tongue
- English
- Weight
- 185 KB
- Volume
- 27
- Category
- Article
- ISSN
- 0914-8779
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Six children received etoposide as the single agent for treatment of Langerhans cell histiocytosis (LCH; histiocytosis X). Five were less than 2 years old at diagnosis. All had multiorgan involvement; one had liver and pulmonary dysfunction. Two infants also had clinical signs of immune deficiency.
Viana et al. [I] described their experience with etoposide (VP-16) as initial therapy in the management of patients with Langerhans cell histiocytosis (LCH). However, caution should be used in advocating the use of an epipodophyllotoxin as the "drug of choice" for the treatment of this disorder. Alt
## Abstract The aim of this study was to investigate the regional importance of Ξ³Ξ΄ T cells in cutaneous lesions of Langerhans' cell histiocytosis. Six cases of Langerhans' cell histiocytosis were investigated by immunohistochemical techniques (alkaline phosphataseβantialkaline phosphatase complex a